美股新聞 標題聯播 · 近 24 小時 294 則 · 33 個來源 · 最新 9/20 03:26
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · JAZZ近 30 天 14 則 · 第 1 / 1 頁
- Jazz Pharmaceuticals (JAZZ) Places An $820M Epilepsy Bet
- Jazz Pharmaceuticals (JAZZ) Eyes Ziihera Trials In Breast Colorectal And Lung Cancer
- Jazz Pharmaceuticals Sees Meaningful Long-Term Value From Ziihera's Pursuits Beyond GEA, UBS Says
- AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study
- Quoin in line for priority review voucher if rare paediatric drug approved
- Jazz (JAZZ) Says Ziihera Beat Trastuzumab on Overall Survival. Can it Replace the First-Line HER2 Backbone?
- Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?
- Duncan Ferguson Joins Neovii Pharmaceuticals AG to Lead Global Commercial Expansion as Chief Commercial Officer
- Stocks making big moves yesterday: Jazz Pharmaceuticals, SAIC, Herbalife, AGCO, and Deere
- Axsome Begins Phase III Study on AXS-05 for Smoking Cessation
- JAZZ Rises on Updated OS Results From Gastric Cancer Study
- Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA
- Jazz Pharmaceuticals Shares May Have Room for Further Appreciation, RBC Says
- Will Ziihera’s First‑Line HER2‑Positive GEA Approval Change Jazz Pharmaceuticals’ (JAZZ) Oncology Narrative
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。